Oasmia Initiating Phase II Study of Drug in Canine Lymphoma


Oasmia Pharmaceutical AB announced today that the company has initiated a clinical Phase II study of Doxophos Vet for the treatment of canine lymphoma.

This study will be conducted at two clinics in the United States and Sweden, respectively. It includes five dose cycles of Doxophos Vet, which contains the active ingredient in doxorubicin, a commonly used chemotherapy drug in humans.

The primary endpoint is the response rate in the treated dogs after five cycles.

CEO of Oasmia said study is an important step for vetrinarians

”The continued development of this unique pharmaceutical is an important step for us, and for all dog owners," said Julian Aleksov, CEO of Oasmia. "It is also an important step for veterinarians, since Doxophos Vet will be a treatment for dogs evaluated on dogs."

”With Doxophos Vet, we can have a pharmaceutical which is specialized for dogs with this very common type of cancer," said Aleksoy.

Currently there is no specialized veterinary treatment for canine lymphoma.

Source: Globe News Wire

Photo by Luke Ma

LymphomaInfo Social